Abstract
BackgroundThe role of TMEM176A in human hepatocellular carcinoma (HCC) is unknown. This study explored the epigenetic regulation and function of TMEM176A in human HCC.Materials and methodsTwelve HCC cell lines and 126 cases of primary cancer were analyzed. Methylation-specific PCR, immunohistochemistry, flow cytometry, and xenograft mouse models were employed.ResultsTMEM176A was highly expressed in SNU387, SNU182, Huh1, and SNU475 cells; reduced expression was observed in HepG2 and PLC/PRF/5 cells; and no expression was found in SNU449, HBXF344, SMMC7721, Huh7, and LM3 cells. Unmethylation of the TMEM176A promoter was detected in SNU387, SNU182, Huh1, and SNU475 cells; partial methylation was observed in HepG2 and PLC/PRF/5 cells; and complete methylation was found in SNU449, HBXF344, SMMC7721, Huh7, and LM3 cells. Upon treatment with 5-Aza-2-deoxycytidine, re-expression of TMEM176A was detected in SNU449, HBXF344, SMMC7721, Huh7, and LM3 cells; increased expression of TMEM176A was observed in HepG2 and PLC/PRF/5 cells; and no expression changes were found in SNU387, SNU182, Huh1, and SNU475 cells. The TMEM176A promoter region was methylated in 75.4% (95/126) of primary human HCC. Reduced expression of TMEM176A was associated with promoter region methylation (P < 0.05). No association was found between TMEM176A promoter methylation and age, gender, HBV infection, liver cirrhosis, tumor size, lymph node metastasis, vessel cancerous embolus, number of lesions, and TNM stage (all P > 0.05). These results demonstrated that the expression of TMEM176A is regulated by promoter region methylation. Methylation of the TMEM176A promoter was significantly associated with tumor cell differentiation (P < 0.05) and was an independent prognostic factor for poor 3-year overall survival (OS, P < 0.05). TMEM176A expression induced cell apoptosis; inhibited cell proliferation, migration, and invasion; suppressed human HCC cell xenograft growth in mice; and inhibited ERK signaling in HCC cells.ConclusionThe promoter region of TMEM176A is frequently methylated in human HCC, and the expression of TMEM176A is regulated by promoter region methylation. Methylation of the TMEM176A promoter may serve as a diagnostic and prognostic marker in HCC. TMEM176A suppresses HCC growth by inhibiting the ERK signaling pathway.
Highlights
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of cancer-related death worldwide [1, 2]
These results demonstrated that the expression of TMEM176A is regulated by promoter region methylation
The promoter region of TMEM176A is frequently methylated in human hepatocellular carcinoma (HCC), and the expression of TMEM176A is regulated by promoter region methylation
Summary
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of cancer-related death worldwide [1, 2]. All MS4A genes are clustered on chromosome 11q in humans in a region with linkage to allergy [10]. Two MS4A-related genes, TMEM176A and TMEM176B, are located on chromosome 7. TMEM176A and TMEM176B transcripts were undetected or detected at only trace levels in most samples of normal human blood or tonsillar B cells, and tissue expression was broad for both TMEM176 genes, suggesting that they have generalized rather than cell type-specific functions [15]. TMEM176A is located in human chromosome 7q36.1, a region where there is a frequent loss of heterozygosity in human cancer [16, 17]. This study explored the epigenetic regulation and function of TMEM176A in human HCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
